Cargando…

Regulation of miR‐200c and miR‐141 by Methylation in Prostate Cancer

BACKGROUND: In prostate cancer (PCa), abnormal expression of several microRNAs (miRNAs) has been previously reported. Increasing evidence shows that aberrant epigenetic regulation of miRNAs is a contributing factor to their altered expression in cancer. In this study, we investigate whether expressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynch, Seodhna M., O'Neill, Karla M., McKenna, Michael M., Walsh, Colum P., McKenna, Declan J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082568/
https://www.ncbi.nlm.nih.gov/pubmed/27198154
http://dx.doi.org/10.1002/pros.23201
_version_ 1782463083738824704
author Lynch, Seodhna M.
O'Neill, Karla M.
McKenna, Michael M.
Walsh, Colum P.
McKenna, Declan J.
author_facet Lynch, Seodhna M.
O'Neill, Karla M.
McKenna, Michael M.
Walsh, Colum P.
McKenna, Declan J.
author_sort Lynch, Seodhna M.
collection PubMed
description BACKGROUND: In prostate cancer (PCa), abnormal expression of several microRNAs (miRNAs) has been previously reported. Increasing evidence shows that aberrant epigenetic regulation of miRNAs is a contributing factor to their altered expression in cancer. In this study, we investigate whether expression of miR‐200c and miR‐141 in PCa is related to the DNA methylation status of their promoter. METHODS: PCR analysis of miR‐200c and miR‐141, and CpG methylation analysis of their common promoter, was performed in PCa cell‐lines and in archived prostate biopsy specimens. The biological significance of miR‐200c and miR‐141 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets DNMT3A and TET1/TET3 was investigated. The effect on promoter methylation status in cells treated with demethylating agents was also examined. RESULTS: miR‐200c and miR‐141 are both highly elevated in LNCaP, 22RV1, and DU145 cells, but significantly reduced in PC3 cells. This correlates inversely with the methylation status of the miR‐200c/miR‐141 promoter, which is unmethylated in LNCaP, 22RV1, and DU145 cells, but hypermethylated in PC3. In PC3 cells, miR‐200c and miR‐141 expression is subsequently elevated by treatment with the demethylating drug decitabine (5‐aza‐2′deoxycytidine) and by knockdown of DNA methyltransferase 1 (DNMT1), suggesting their expression is regulated by methylation. Expression of miR‐200c and miR‐141 in prostate biopsy tissue was inversely correlated with methylation in promoter CpG sites closest to the miR‐200c/miR‐141 loci. In vitro, over‐expression of miR‐200c in PC3 cells inhibited growth and clonogenic potential, as well as inducing apoptosis. Expression of the genes DNMT3A and TET1/TET3 were down‐regulated by miR‐200c and miR‐141 respectively. Finally, treatment with the soy isoflavone genistein caused demethylation of the promoter CpG sites closest to the miR‐200c/miR‐141 loci resulting in increased miR‐200c expression. CONCLUSIONS: Our findings provide evidence that miR‐200c and miR‐141 are under epigenetic regulation in PCa cells. We propose that profiling their expression and methylation status may have potential as a novel biomarker or focus of therapeutic intervention in the diagnosis and prognosis of PCa. Prostate 76:1146–1159, 2016. © 2016 The Authors. The Prostate published by Wiley Periodicals, Inc.
format Online
Article
Text
id pubmed-5082568
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-50825682016-11-09 Regulation of miR‐200c and miR‐141 by Methylation in Prostate Cancer Lynch, Seodhna M. O'Neill, Karla M. McKenna, Michael M. Walsh, Colum P. McKenna, Declan J. Prostate Original Articles BACKGROUND: In prostate cancer (PCa), abnormal expression of several microRNAs (miRNAs) has been previously reported. Increasing evidence shows that aberrant epigenetic regulation of miRNAs is a contributing factor to their altered expression in cancer. In this study, we investigate whether expression of miR‐200c and miR‐141 in PCa is related to the DNA methylation status of their promoter. METHODS: PCR analysis of miR‐200c and miR‐141, and CpG methylation analysis of their common promoter, was performed in PCa cell‐lines and in archived prostate biopsy specimens. The biological significance of miR‐200c and miR‐141 expression in prostate cancer cells was assessed by a series of in vitro bioassays and the effect on proposed targets DNMT3A and TET1/TET3 was investigated. The effect on promoter methylation status in cells treated with demethylating agents was also examined. RESULTS: miR‐200c and miR‐141 are both highly elevated in LNCaP, 22RV1, and DU145 cells, but significantly reduced in PC3 cells. This correlates inversely with the methylation status of the miR‐200c/miR‐141 promoter, which is unmethylated in LNCaP, 22RV1, and DU145 cells, but hypermethylated in PC3. In PC3 cells, miR‐200c and miR‐141 expression is subsequently elevated by treatment with the demethylating drug decitabine (5‐aza‐2′deoxycytidine) and by knockdown of DNA methyltransferase 1 (DNMT1), suggesting their expression is regulated by methylation. Expression of miR‐200c and miR‐141 in prostate biopsy tissue was inversely correlated with methylation in promoter CpG sites closest to the miR‐200c/miR‐141 loci. In vitro, over‐expression of miR‐200c in PC3 cells inhibited growth and clonogenic potential, as well as inducing apoptosis. Expression of the genes DNMT3A and TET1/TET3 were down‐regulated by miR‐200c and miR‐141 respectively. Finally, treatment with the soy isoflavone genistein caused demethylation of the promoter CpG sites closest to the miR‐200c/miR‐141 loci resulting in increased miR‐200c expression. CONCLUSIONS: Our findings provide evidence that miR‐200c and miR‐141 are under epigenetic regulation in PCa cells. We propose that profiling their expression and methylation status may have potential as a novel biomarker or focus of therapeutic intervention in the diagnosis and prognosis of PCa. Prostate 76:1146–1159, 2016. © 2016 The Authors. The Prostate published by Wiley Periodicals, Inc. John Wiley and Sons Inc. 2016-05-16 2016-09-15 /pmc/articles/PMC5082568/ /pubmed/27198154 http://dx.doi.org/10.1002/pros.23201 Text en © 2016 The Authors. The Prostate published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Lynch, Seodhna M.
O'Neill, Karla M.
McKenna, Michael M.
Walsh, Colum P.
McKenna, Declan J.
Regulation of miR‐200c and miR‐141 by Methylation in Prostate Cancer
title Regulation of miR‐200c and miR‐141 by Methylation in Prostate Cancer
title_full Regulation of miR‐200c and miR‐141 by Methylation in Prostate Cancer
title_fullStr Regulation of miR‐200c and miR‐141 by Methylation in Prostate Cancer
title_full_unstemmed Regulation of miR‐200c and miR‐141 by Methylation in Prostate Cancer
title_short Regulation of miR‐200c and miR‐141 by Methylation in Prostate Cancer
title_sort regulation of mir‐200c and mir‐141 by methylation in prostate cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5082568/
https://www.ncbi.nlm.nih.gov/pubmed/27198154
http://dx.doi.org/10.1002/pros.23201
work_keys_str_mv AT lynchseodhnam regulationofmir200candmir141bymethylationinprostatecancer
AT oneillkarlam regulationofmir200candmir141bymethylationinprostatecancer
AT mckennamichaelm regulationofmir200candmir141bymethylationinprostatecancer
AT walshcolump regulationofmir200candmir141bymethylationinprostatecancer
AT mckennadeclanj regulationofmir200candmir141bymethylationinprostatecancer